PPIAL4D Inhibitors
Chemical inhibitors of PPIAL4D employ a variety of mechanisms to arrest its enzymatic activity. Cyclosporin A and Sanglifehrin A directly target the isomerase function of PPIAL4D by binding to it and preventing it from catalyzing the isomerization of peptide bonds. Such inhibition can disrupt the proper folding of proteins that PPIAL4D acts upon, which is essential for their function. FK506 shares a similar mode of action, potentially exhibiting cross-reactivity due to its affinity for proteins in the peptidyl-prolyl isomerase family, thereby also inhibiting the functional activity of PPIAL4D. Geldanamycin indirectly affects PPIAL4D by binding to Hsp90, a molecular chaperone that assists in the correct folding of many proteins, including PPIAL4D. As a result, the stability and function of PPIAL4D can be compromised by the loss of Hsp90 activity.
In contrast, Demethoxyviridin and Alisertib operate upstream of PPIAL4D by targeting kinases involved in signaling pathways. Although these compounds do not directly inhibit PPIAL4D, their action can lead to a cascade of effects that result in a reduced requirement for PPIAL4D's activity. Similarly, Leflunomide's inhibition of dihydroorotate dehydrogenase can lead to a decrease in RNA and DNA synthesis, which may reduce the cellular demand for the PPIAL4D-mediated protein folding process. Omacetaxine and Silvestrol disrupt protein synthesis by interfering with distinct steps in the translation process, which can decrease the overall levels of proteins that would normally require PPIAL4D's isomerase activity. Lastly, Bortezomib and Lenalidomide meddle with the protein turnover process, which can indirectly influence the functional activity of PPIAL4D by altering the degradation and synthesis of its potential substrate proteins or interaction partners. These varied approaches to inhibiting PPIAL4D converge on the common outcome of disrupting the protein's normal function within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A binds to the cyclophilin family of proteins, inhibiting their peptidyl-prolyl isomerase activity. Given that PPIAL4D is a member of the cyclophilin family, Cyclosporin A would inhibit PPIAL4D's isomerase activity, which is crucial for protein folding and function. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $182.00 $661.00 | 10 | |
Demethoxyviridin is a kinase inhibitor that targets signaling pathways involving kinases. Although not a direct inhibitor of PPIAL4D, by inhibiting upstream kinases, it might disrupt signaling cascades that rely on PPIAL4D's peptidyl-prolyl isomerase activity for signal propagation. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK506 (Tacrolimus) binds to FKBP family proteins and inhibits their activity. As PPIAL4D is a peptidyl-prolyl isomerase, FK506 may exhibit a cross-reactivity and inhibit PPIAL4D's enzymatic activity, which is critical for its role in various cellular processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in cell growth and proliferation pathways. By inhibiting mTOR, Rapamycin might reduce the cellular activities that are dependent on PPIAL4D function, as PPIAL4D may participate in pathways that are modulated by mTOR activity. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90 and inhibits its chaperone activity. As PPIAL4D may require the proper protein folding assisted by Hsp90, inhibition of Hsp90 by Geldanamycin could lead to a functional inhibition of PPIAL4D by disrupting its folding and stability. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. Though not a direct inhibitor, by disrupting Aurora kinase A activity, Alisertib could impair cell cycle progression and indirectly reduce the functional requirement for PPIAL4D in the cell cycle, where its isomerase activity may be necessary. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, leading to reduced pyrimidine synthesis. While not a direct inhibitor of PPIAL4D, reduced pyrimidine levels can lead to decreased RNA and DNA synthesis, which may lower the demand for proteins like PPIAL4D involved in cell proliferation. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $51.00 $123.00 $178.00 | 11 | |
Omacetaxine inhibits protein synthesis by binding to the A-site cleft in the ribosome. This inhibition could reduce the overall protein synthesis rate, thereby potentially decreasing the functional requirement for PPIAL4D in protein folding and assembly processes within the cell. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor; by inhibiting proteasome activity, it could lead to increased cellular stress and a potential upregulation in the need for chaperone proteins. However, with PPIAL4D inhibited, cells may not be able to respond adequately to the stress, indirectly inhibiting PPIAL4D's function in the response to unfolded protein accumulation. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide modulates the ubiquitin-proteasome pathway. This modulation could affect the turnover of proteins that interact with PPIAL4D, leading to a functional inhibition of PPIAL4D by altering its substrate availability or interaction dynamics. | ||||||